secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regenerative Medical Technology Group Inc. (RMTG)
CIK:        0001760026
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001213900-24-099837
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RMTG reports Q3 sales up 52% YoY, achieves operational profitability, gross margin 75%
--------------------------------------------------------------------------------

- Sales rose 52% YoY to $986,308; gross profit margin reached 75% for Q3 2024.
- Patient procedures revenue surged over 370% YoY, now 37% of revenue versus 12% last year.
- Company achieved operational profitability, defined as revenue minus all operating expenses excluding interest and taxes.
- Dubai clinic expected to launch next week; plans for a manufacturing facility in Cancun to produce exosomes and stem cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/0001213900-24-099837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/ea0221755-8k_regenerative.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-099837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer